Kendra BrackenFerguson - Carmell Therapeutics Chief Officer
| CTCX Stock | 0.28 0.02 7.69% |
Executive
Kendra BrackenFerguson is Chief Officer of Carmell Therapeutics
| Address | 2403 Sidney Street, Pittsburgh, PA, United States, 15203 |
| Phone | 919 313 9633 |
| Web | https://www.carmellcosmetics.com |
Carmell Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.8464) % which means that it has lost $0.8464 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.7639) %, meaning that it created substantial loss on money invested by shareholders. Carmell Therapeutics' management efficiency ratios could be used to measure how well Carmell Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.25 in 2024. Return On Capital Employed is likely to rise to -0.19 in 2024. At this time, Carmell Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 62.8 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 952 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| David Marks | Immix Biopharma | N/A | |
| James Wang | Virax Biolabs Group | N/A | |
| Gael Hedou | Sonnet Biotherapeutics Holdings | 52 | |
| Mitchell MD | Palisade Bio | 46 | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Ryker Willie | Palisade Bio | N/A | |
| Daniel MBA | Biodexa Pharmaceticals | N/A | |
| Jose MD | Allarity Therapeutics | 67 | |
| Steve Ellul | Biodexa Pharmaceticals | N/A | |
| Ben JD | Immix Biopharma | N/A | |
| Douglas MBA | Unicycive Therapeutics | 62 | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Joerg Heyer | Palisade Bio | N/A | |
| Lily Fu | Virax Biolabs Group | N/A | |
| Joel Yeung | Virax Biolabs Group | N/A | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| Stephen McAndrew | Sonnet Biotherapeutics Holdings | 70 | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Fiona Sharp | Biodexa Pharmaceticals | N/A | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.76 | ||||
| Return On Asset | -0.85 |
Carmell Therapeutics Leadership Team
Elected by the shareholders, the Carmell Therapeutics' board of directors comprises two types of representatives: Carmell Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Carmell. The board's role is to monitor Carmell Therapeutics' management team and ensure that shareholders' interests are well served. Carmell Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Carmell Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James MD, Founder | ||
| Kendra BrackenFerguson, Chief Officer | ||
| Rajiv Shukla, Executive Chairman | ||
| Lee Weiss, Founder | ||
| Phil Campbell, Founder Officer | ||
| Bryan Cassaday, Chief Officer |
Carmell Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Carmell Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.76 | ||||
| Return On Asset | -0.85 | ||||
| Operating Margin | (96.71) % | ||||
| Current Valuation | 5.41 M | ||||
| Shares Outstanding | 20.91 M | ||||
| Shares Owned By Insiders | 33.66 % | ||||
| Shares Owned By Institutions | 19.49 % | ||||
| Number Of Shares Shorted | 429.72 K | ||||
| Price To Book | 1.91 X | ||||
| Price To Sales | 468.34 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Carmell Stock Analysis
When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.